This is a randomised, double-blind, parallel group, placebo-controlled study designed to
evaluate the efficacy and safety of a fixed 30 mg dose of benralizumab administered
subcutaneously for patients with a history of asthma exacerbations and uncontrolled asthma
receiving medium to high-dose inhaled corticosteroid plus long-acting 2-agonist (ICS-LABA)
with or without oral corticosteroids and additional asthma controllers.
Approximately 666 patients will be randomised. Patients will be stratified by country/region,
age group (adult or adolescent), and peripheral blood eosinophil count at time of Visit 1
(<300 or 300 cells/L).All the patients will be randomised to either placebo or benralizumab
(1:1 ratio) for a 48-weeks treatment, every 4 weeks for the first 3 doses and then every 8
Clinical Study Identifier
Last Modified on
22 November 2020
How clear was the trial content above?
Adding a note
Select a piece of text and start making personal notes.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.